About Clare Ozawa
Form D filings for 858 Therapeutics from 2020 to 2024 list Clare Ozawa as director.
Clare Ozawa first appears on SEC filings in 2020.
Experience
This experience comes from SEC filings. The years are when the filings name Clare Ozawa in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Clare Ozawa works with at each company, as listed on that company's latest Form D.
858 Therapeutics, Inc. · Form D, Jul 11, 2024
JV
James Veal
Executive officer
JH
Jane Huang
Director
MM
Monal Mehta
Director
SJ
Stafford Jeffrey
Executive officer and director
AB
Ali Behbahani
Director
KM
Katherine Bell-McGuinn
Executive officer